step
adjust ep exclud non-cash one-tim item
headquart foster citi ca one largest biotechnolog compani world
develop drug hepat hcv hiv oncolog
juli gilead report strong result revenu vs estim
ep ep beat driven solid top-line lower-than-expect tax rate compani lower tax
guidanc
manag step unexpectedli announc ceo john milligan step
ye togeth chairman john martin founding/key member grew compani
infanc along ex-chief scientif offic step apr new ceo like rebuild
growth expertis oncolog nash new therapeut area believ fundament
stori remain strong sharehold disappoint capit alloc strategi lack
transform deal despit strong launch yescarta kite deal satisfi investor
believ size deal investor hope given chang
manag unlik compani anoth sizabl deal new ceo start
hep gener revenu beat due stabil patient start
price strength gild hiv sale could relief investor light caus
season yescarta gener sale vs estim compar
increas forecast yescarta expect reach sale
minim impact merck hcv price cut last week merck announc cut hep drug price
estim cut slightli lower estim cost
per patient gild regimen merck gener sale took
signific patient share launch mavyret howev sinc abbv week
regimen like prefer mrk week regimen believ price cut would impact
current market dynam believ continu maintain share medicaid popul
domin commerci medicar
reiter buy maintain buy recommend share pmv estim
per share repres margin safeti current level near term catalyst includ manag
chang growth yescarta readout bcma phi trial
million except per share
exclud non-cash one-tim item
million except per share
hiv
current market discount pmv
after-tax payment buy option holder privat market valu
jing research analyst prepar report herebi certifi view express report accur reflect analyst person view subject
compani secur research analyst receiv direct indirect compens express specif recommend
view report
public data june buy
